China Medical System Holdings Ltd (CMS, HKG: 0867) has announced a licensing agreement with Jiangxi Xihong Biopharma Co., Ltd, granting CMS exclusive promotion, marketing, and commercialization rights for Xihong Biopharma’s injectable polycaprolactone microspheres filler and injectable hydroxyapatite microspheres filler in China mainland, Hong Kong, Macau, and Taiwan. Both Category III medical devices are designed for subcutaneous or deep dermal injection to correct moderate-to-severe nasolabial groove wrinkles and are currently in the regulatory study phase in China.
Financial details of the agreement have not been disclosed.- Flcube.com
